by Plus Therapeutics | Dec 18, 2025 | LM
Expert Insights: Dr. Andrew Brenner on the Path Forward In a recent video interview with Sabrina McCrear of AJMC – The American Journal of Managed Care, Andrew Brenner, MD, PhD, provided a deeper look into the significance of the SABCS presentations. Dr. Brenner...
by Plus Therapeutics | Dec 16, 2025 | Uncategorized
What Are Targeted Radiotherapeutics? Targeted radiotherapeutics are designed to deliver radiation from within the body, directly to tumor sites, using advanced targeting mechanisms that guide radioactive payloads to cancer cells with high precision. Unlike traditional...
by Plus Therapeutics | Dec 15, 2025 | LM
At the 2025 San Antonio Breast Cancer Symposium (SABCS), Plus Therapeutics and its clinical partners shared important progress in the fight against leptomeningeal metastases (LM) with the presentation of Phase 1 dose escalation results from the ReSPECT-LM clinical...
by Plus Therapeutics | Dec 4, 2025 | Uncategorized
Plus Therapeutics is pleased to announce the presentation of three positive clinical data updates at the World Federation of Neuro-Oncology Societies (WFNOS) / Society for Neuro-Oncology (SNO) 2025 Annual Meeting. These new findings advance the Company’s growing body...
by Plus Therapeutics | Dec 3, 2025 | Uncategorized
Plus Therapeutics’ growing momentum in central nervous system (CNS) oncology was recently spotlighted when President & CEO Marc Hedrick, MD, joined host Ira S. Pastor on the Progress, Potential, and Possibilities podcast. The in-depth discussion provides a clear,...
Recent Comments